Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.

You may also be interested in...



Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Valeant’s One-Two Punch Sends Allergan Ducking And Weaving; Who’s Next In The Ring?

Valeant’s partnership with activist investor William Ackman to acquire Allergan for around $46 billion would be Valeant’s largest acquisition but sets the stage for a protracted fight.

Valeant’s Expansion Ambitions Leads To Allergan’s Door

Potential $50 billion deal would buttress Valeant as a top ophthalmology and dermatology drug marketer.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel